This trial will study the effects of inebilizumab in children 2-18 years old with NMOSD who have AQP4-IgG antibodies.
- Neuromyelitis Optica Spectrum Disorders
16 Primary · 8 Secondary · Reporting Duration: Baseline, Week 1, Week 2, Week 28, Week 80
Side Effects for
Awards & Highlights
1 Treatment Group
1 of 1
15 Total Participants · 1 Treatment Group
Primary Treatment: Inebilizumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 2 - 17 · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|UC San Diego Altman Clinical and Translational Research Institute (ACTRI) Building||100.0%|
What portion of applicants met pre-screening criteria?
What state do they live in?
How responsive is this trial?
Average response time
- < 1 Day
Typically responds via
Most responsive sites:
- UC San Diego Altman Clinical and Translational Research Institute (ACTRI) Building: < 24 hours
Frequently Asked Questions
Am I eligible to partake in this investigation?
"The requirements to be accepted into this clinical trial are specific; potential participants must have neuromyelitis optica and fall between the ages of 2 and 17. The maximum capacity for enrolment is 15 individuals." - Anonymous Online Contributor
Does this research encompass participants older than two decades in age?
"This medical trial is seeking participants aged between 2 and 17 years old." - Anonymous Online Contributor
Is Inebilizumab considered a risk-free treatment option for patients?
"Preclinical research indicates that Inebilizumab is reasonably safe, thus warranting a score of 2. Despite this safety evidence, no clinical studies have been conducted to measure the efficacy of this drug." - Anonymous Online Contributor
Is the recruitment phase of this research still ongoing?
"Affirmative. According to clinicaltrials.gov, this medical experiment was posted on August 25th 2022 and is still currently recruiting participants; 15 patients are needed at 4 distinct sites." - Anonymous Online Contributor
How many individuals are partaking in this medical study?
"All in all, 15 compliant participants are necessary to keep the trial running. Horizon Therapeutics Ireland DAC will be managing it from several different sites including University of Texas Southwestern Medical Centre and Massachusetts General Hospital respectively located in Dallas and Lexington." - Anonymous Online Contributor
Are there extensive facilities that are presently conducting research with this study in North America?
"This study is being conducted at 4 separate medical institutions, such as the University of Texas Southwestern Medical Center in Dallas and Massachusetts General Hospital in Lexington. Additionally, UC San Diego Altman Clinical and Translational Research Institute (ACTRI) Building in La Jolla has also been enlisted along with other centres." - Anonymous Online Contributor